Retatrutide adds glucagon receptor agonism, which may contribute to increased energy expenditure, enhanced hepatic lipolysis, and liver fat reduction mechanisms absent from Tirzepatides profile
In addition to differences in structure (e.g., exendin-4 based peptides vs
Ongoing Phase 3 work (tracked on ClinicalTrials.gov ) will give clearer body-composition endpoints
For weight loss purposes, doctors will start with a lower dosage of subcutaneous injections and slowly work up depending on how the patient reacts to the medication
Pierre warns it may indicate severe and potentially dangerous digestive issues
Studies conducted on patients with obesity and diabetes suggest that retatrutide may be better at zeroing in on fat, preserving more lean muscle mass than earlier generations of injectable GLP-1 drugs like Ozempic and Mounjaro